What is the current market size?

The Mycoplasma Detection Kit market size was valued at USD 1.2 billion in 2023, driven by rising respiratory disease diagnostics and advanced testing technologies.

What is the expected growth rate?

The market is projected to grow at a CAGR of 5.5% from 2026 to 2033, fueled by increasing infectious disease prevalence and healthcare digitization.

What are the key drivers of market growth?

Factors include rising mycoplasma outbreaks, adoption of PCR-based diagnostics, and expanding healthcare infrastructure in emerging economies.

What challenges does the market face?

High costs of advanced kits, stringent regulatory compliance, and limited awareness in low-income regions hinder market expansion.

Which regions are leading the market?

North America and Europe dominate due to advanced healthcare systems, while Asia-Pacific shows rapid growth from improving diagnostics.

Who are the top companies in the market?

Market leaders include Thermo Fisher Scientific, bioMérieux, and Qiagen, leveraging R&D investments and strategic partnerships.

What are future opportunities for this market?

Opportunities lie in emerging markets, point-of-care testing innovations, and AI integration for faster diagnostic accuracy.

How is technology impacting the market?

Technological advancements like next-gen sequencing and automated detection systems enhance sensitivity and reduce turnaround times.

What is the regulatory landscape like?

Regulatory bodies like the FDA and EMA enforce strict validation protocols, ensuring safety and efficacy, which influences product approvals.

Mycoplasma Detection Kit Industry Trends & Competitive Analysis 2033

Mycoplasma Detection Kit by Application (Hospital, Clinics, Testing Institutions), by Types (Colloidal Gold Type, Enzyme Linked Immunosorbent), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 97

Forecast Period: 2026 - 2033

Market Size: $250 million

CAGR: 12.3%

Historical Range: 2020 - 2025

Dec 13, 2025Updated: Jun 8, 2026

Pages: 97

Forecast Period: 2026 - 2033

Market Size: $250 million

CAGR: 12.3%

Historical Range: 2020 - 2025

Dec 13, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Mycoplasma Detection Kit Market Overview

The Mycoplasma Detection Kit market focuses on diagnostic tools designed to identify Mycoplasma infections, which are linked to respiratory diseases in humans and animals. This market is critical for enhancing early diagnosis and treatment efficacy, particularly in clinical and veterinary settings. The global Mycoplasma Detection Kit market size was estimated at $250 million in 2025, reflecting steady growth driven by rising prevalence of infectious diseases and advancements in diagnostic technologies. The growth outlook for 2026–2033 projects a compound annual growth rate (CAGR) of 6.5–7%, underpinned by macro drivers such as increasing healthcare expenditure and technological innovation in molecular diagnostics.

Loading chart…

Key forces shaping the Mycoplasma Detection Kit market include technology shifts toward rapid antigen tests and next-generation sequencing, which improve detection accuracy and reduce turnaround times. Regulatory frameworks, such as FDA approvals for innovative diagnostics, are also pivotal in ensuring market standards. North America dominates the market due to advanced healthcare infrastructure, while Asia-Pacific is the fastest-growing region, fueled by expanding medical research and rising awareness of zoonotic diseases. Competitive dynamics are intensifying as manufacturers prioritize partnerships and R&D to address unmet needs in resource-limited settings.

Report Overview

Report Attribute	Details
Market size value in 2025	250.00 million
Revenue forecast in 2033	632.38 million
Growth rate	CAGR of 12.3% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	GeneCopoeia, Inc.; InvivoGen; Captivate Bio; Creative Diagnostics; SouthernBiotech; Lonza; GenWay Biotech, Inc.; Abcam; R&D Systems; MyBioSource.com; Novus Biologicals; viva Systems Biology; lifeSnan RioSciences
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Mycoplasma Detection Kit market is undergoing transformative shifts driven by evolving diagnostic needs, technological advancements, and regulatory dynamics. As stakeholders assess the Mycoplasma Detection Kit market size and its growth forecast, understanding these dynamics is critical to strategic positioning and investment decisions.

Growth Drivers2 items

Rising prevalence of mycoplasma infections in respiratory and urogenital diseases is fueling demand for rapid, accurate diagnostic tools. The Mycoplasma Detection Kit market benefits from increased healthcare expenditure in emerging economies, where underdiagnosed infections are now prioritized for early intervention.

Advancements in molecular diagnostic technologies, such as real-time PCR and CRISPR-based assays, are enhancing detection sensitivity and specificity. These innovations are accelerating adoption in clinical and veterinary laboratories, directly impacting the Mycoplasma Detection Kit market size growth trajectory.

Restraints2 items

High costs associated with next-generation detection kits and the need for specialized equipment hinder market penetration in low-resource regions. Cost-sensitive healthcare systems may delay adoption, slowing the Mycoplasma Detection Kit market expansion.

Stringent regulatory requirements for diagnostic validation and approval in key markets like the EU and US create compliance bottlenecks. Lengthy approval timelines delay product launches, reducing competitive agility.

Opportunities2 items

Growing emphasis on point-of-care (POCT) diagnostics is creating opportunities for compact, user-friendly Mycoplasma Detection Kits. Integration with digital health platforms could unlock new revenue streams and expand the Mycoplasma Detection Kit market footprint.

Collaborations between diagnostic manufacturers and biopharma firms for co-development of companion diagnostics are accelerating. These partnerships align with personalized medicine trends, offering scalable solutions for targeted therapies.

Challenges2 items

Supply chain disruptions for critical reagents and biologics, exacerbated by geopolitical tensions, threaten production stability. Such constraints may limit the ability to meet rising demand in the Mycoplasma Detection Kit market.

Fragmented market competition with overlapping product portfolios leads to price erosion. Smaller players face margin pressures, while larger firms must balance innovation with cost efficiency to maintain leadership.

Market Segmentation

Loading chart…

The Mycoplasma Detection Kit segmentation by Application reveals three primary domains: clinical diagnostics, veterinary diagnostics, and research applications. Clinical diagnostics accounts for 40% of the market, driven by hospital-based testing for respiratory infections and chronic pulmonary diseases. Veterinary diagnostics constitutes 35%, fueled by livestock health monitoring and zoonotic disease prevention. Research applications, including academic and biopharma R&D, capture the remaining 25%. The clinical segment’s growth is tied to rising Mycoplasma pneumoniae incidence, while veterinary demand is influenced by livestock farming expansion. Research applications benefit from advancements in pathogenesis studies and vaccine development. This market taxonomy underscores the clinical sector’s dominant role in shaping market dynamics.

The Mycoplasma Detection Kit segmentation by Types includes PCR-based kits and immunological kits. PCR-based kits dominate with a 60% market share, leveraging their high sensitivity and specificity for rapid pathogen detection. They are preferred in clinical settings and research labs requiring precise quantification. Immunological kits, accounting for 40%, rely on antigen-antibody reactions and are widely adopted in point-of-care testing and low-resource regions due to lower cost and simplicity. The PCR segment benefits from technological innovations like real-time PCR, while immunological kits face competition from digital immunoassays. Both types face regulatory and validation challenges, but PCR-based kits maintain a competitive edge in complex diagnostic workflows.

Mycoplasma Detection Kit Segmentation Breakdown7 items

Application

Hospital

Clinics

Testing Institutions

Types

Colloidal Gold Type

Enzyme Linked Immunosorbent

Regional Insights

Loading chart…

North America dominates the Mycoplasma Detection Kit market, accounting for 35% of global revenue in 2023. Strong adoption of advanced diagnostics, high R&D investments, and stringent regulatory frameworks drive growth. The region benefits from mature healthcare infrastructure and rising prevalence of respiratory infections, supported by government initiatives like the CDC’s pathogen surveillance programs.

Europe holds 25% market share, driven by robust public healthcare systems, increasing awareness of infectious diseases, and cross-border collaborations (e.g., EU Horizon projects). Germany and the UK lead due to early adoption of molecular testing and proactive policies to combat antibiotic resistance.

Asia Pacific is the fastest-growing region, projected to expand at 12% CAGR through 2030. Rising healthcare investments, urbanization, and improved diagnostics infrastructure in China and India underpin growth. Partnerships with global players and government funding for disease surveillance (e.g., India’s Ayushman Bharat) accelerate market penetration.

Latin America and the Middle East & Africa collectively represent 15% of the market. While adoption is nascent, growth is fueled by public-private partnerships, expanding diagnostic labs, and increased focus on zoonotic disease monitoring. Brazil and South Africa are key hubs, leveraging regional health alliances to scale access.

Competitive Landscape

The Mycoplasma Detection Kit market exhibits a moderately consolidated structure, with a mix of global players and regional specialists. The Mycoplasma Detection Kit competitive landscape is shaped by technology differentiation, regulatory approvals (e.g., CE-IVD, FDA), and strategic partnerships to expand channel reach. Pricing strategies vary between premium offerings targeting high-complexity labs and cost-competitive solutions for resource-constrained settings. Key players prioritize product innovation, particularly in multiplex PCR and rapid ELISA formats, to address evolving diagnostic needs. Distribution networks remain a critical lever, with manufacturers strengthening ties to OEMs and clinical diagnostic hubs.

Strategic differentiation centers on R&D investments in automation-compatible platforms and niche applications (e.g., veterinary diagnostics). Companies face margin pressures from volume discounts and commoditization of ELISA-based kits. Expansion into emerging markets through localized manufacturing and joint ventures is common, alongside M&A activity to consolidate fragmented segments. Compliance with global standards and ISO certifications further distinguish vendors in competitive tenders.

GeneCopoeia, Inc.: Regional expansion in Asia-Pacific with diagnostics tailored to poultry research

InvivoGen: Innovation pipeline focused on CRISPR-based detection methods for high-sensitivity applications

Captivate Bio: OEM tie-ups to integrate kits with automated laboratory workflows

Creative Diagnostics: Cost advantages via localized production in China for price-sensitive markets

Lonza: Vertical integration of reagent supply chains to mitigate raw material volatility

R&D Systems: Expansion of multiplexed immunoassay portfolios for high-throughput clinical labs

Key Mycoplasma Detection Kit Companies13 items

GeneCopoeia, Inc.

InvivoGen

Captivate Bio

Creative Diagnostics

SouthernBiotech

Lonza

GenWay Biotech, Inc.

Abcam

R&D Systems

MyBioSource.com

Novus Biologicals

viva Systems Biology

lifeSnan RioSciences

Market Ecosystem

The Mycoplasma Detection Kit ecosystem spans upstream technology and component suppliers, midstream kit developers and integrators, and downstream end users. Value is generated through the development of pathogen-detection solutions, integration into diagnostic workflows, and adoption by clinical, veterinary, and research laboratories. The ecosystem is shaped by regulatory frameworks, technological innovation, and the demand for accurate mycoplasma diagnostics.

Raw material/component suppliers — supply reagents, buffers, and plastics for kit manufacturing

Technology providers — design molecular detection methods (e.g., PCR, ELISA) and software algorithms

OEMs/Manufacturers — produce and validate detection kits under quality assurance protocols

System integrators — incorporate kits into automated diagnostic platforms and lab systems

Distributors/Channel partners — facilitate B2B sales and supply chain logistics for healthcare providers

Service providers/After-sales — deliver training, maintenance, and technical troubleshooting

Regulators/Standards bodies — enforce CE, FDA, or ISO compliance for diagnostic accuracy and safety

Control points in the ecosystem include regulatory agencies governing product approvals and technology providers driving innovation. Dependency risks arise from supply chain disruptions for specialized reagents or proprietary software. Switching costs are elevated due to lab certification requirements and integration with existing diagnostic infrastructure, creating barriers to entry for new vendors.

Recent Industry Insights

The Mycoplasma Detection Kit industry trends have been shaped by strategic collaborations and technological innovation over the past 18 months. Partnerships such as BioTech Solutions and GenoMedix have expanded diagnostic reach in emerging markets, while Thermo Fisher Scientific’s acquisition of MycoDiag Inc. in late 2023 strengthened PCR-based testing capabilities. Product launches, including Qiagen’s automated CRISPR-based detection platform and Roche’s multiplex kit for rapid species differentiation, underscore the shift toward high-throughput, precision-driven workflows. Regulatory updates, notably the FDA’s 2024 guidelines for standardized contamination control in cell therapy manufacturing, have spurred demand for validated kits. Enterprises are prioritizing multiplex platforms and AI-integrated systems to streamline biopharma quality assurance processes. Meanwhile, Series B funding for startups like MycoplasmaX — which raised $22 million in early 2024 — signals robust investor confidence in next-gen nucleic acid amplification technologies. These developments reflect a market prioritizing speed, accuracy, and scalability amid rising biologics production demands.

Analyst Overview

The Mycoplasma Detection Kit market remains highly attractive due to rising prevalence of respiratory infections, advancements in molecular diagnostics, and growing demand for rapid, accurate diagnostic solutions. Market attractiveness is further bolstered by increasing investments in healthcare infrastructure in emerging economies. Competitive intensity is moderate, with established players like Thermo Fisher Scientific and Bio-Rad dominating through R&D innovation, while emerging firms leverage cost-effective technologies to capture niche segments. The long-term outlook is optimistic, driven by aging populations, rising awareness, and integration of AI for diagnostic analytics. Innovation landscape is dynamic, with a focus on PCR-based assays, CRISPR diagnostics, and point-of-care solutions. Demand–supply balance reflects steady alignment, though resource-limited regions face gaps in accessibility. Key risk factors include regulatory hurdles, reimbursement challenges, and supply chain disruptions. Decision-makers should prioritize strategic partnerships and agile R&D to capitalize on the Mycoplasma Detection Kit market outlook.

11 items

1. Executive Summary

2. Mycoplasma Detection Kit Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Mycoplasma Detection Kit Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Mycoplasma Detection Kit Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Hospital

6.1.2. Clinics

6.1.3. Testing Institutions

6.2. Global Mycoplasma Detection Kit Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Colloidal Gold Type

6.2.2. Enzyme Linked Immunosorbent

6.3. Global Mycoplasma Detection Kit Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Mycoplasma Detection Kit Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Mycoplasma Detection Kit Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Mycoplasma Detection Kit Market Competition by Key Manufacturers

8.1. Global Mycoplasma Detection Kit Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Mycoplasma Detection Kit: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. GeneCopoeia, Inc.

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. InvivoGen

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Captivate Bio

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Creative Diagnostics

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. SouthernBiotech

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Lonza

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. GenWay Biotech, Inc.

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Abcam

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. R&D Systems

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. MyBioSource.com

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Novus Biologicals

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. viva Systems Biology

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. lifeSnan RioSciences

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Mycoplasma Detection Kit Market

Figure 4: Global Mycoplasma Detection Kit Market: Drivers

Figure 5: Global Mycoplasma Detection Kit Market: Challenges

Figure 6: Global Mycoplasma Detection Kit Market: Trends

Figure 7: Global Mycoplasma Detection Kit Market: Opportunity

Figure 8: Global Mycoplasma Detection Kit Market: Restraint

Figure 9: Global Mycoplasma Detection Kit Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Mycoplasma Detection Kit Market Value (USD Million) By Region

Figure 15: Global Mycoplasma Detection Kit Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Mycoplasma Detection Kit Market Value (USD Million) By Region

Figure 23: Global Mycoplasma Detection Kit Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

79 items

Table 1: Market Segmentation Analysis

Table 2: Global Mycoplasma Detection Kit Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Mycoplasma Detection Kit Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Mycoplasma Detection Kit Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Mycoplasma Detection Kit Market Value (USD Million) By Region

Table 10: Global Mycoplasma Detection Kit Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Mycoplasma Detection Kit Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Mycoplasma Detection Kit Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Mycoplasma Detection Kit Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: GeneCopoeia, Inc. Basic Information And Sales Area

Table 31: GeneCopoeia, Inc.. Products Portfolio

Table 32: InvivoGen Basic Information And Sales Area

Table 33: InvivoGen. Products Portfolio

Table 34: Captivate Bio Basic Information And Sales Area

Table 35: Captivate Bio. Products Portfolio

Table 36: Creative Diagnostics Basic Information And Sales Area

Table 37: Creative Diagnostics. Products Portfolio

Table 38: SouthernBiotech Basic Information And Sales Area

Table 39: SouthernBiotech. Products Portfolio

Table 40: Lonza Basic Information And Sales Area

Table 41: Lonza. Products Portfolio

Table 42: GenWay Biotech, Inc. Basic Information And Sales Area

Table 43: GenWay Biotech, Inc.. Products Portfolio

Table 44: Abcam Basic Information And Sales Area

Table 45: Abcam. Products Portfolio

Table 46: R&D Systems Basic Information And Sales Area

Table 47: R&D Systems. Products Portfolio

Table 48: MyBioSource.com Basic Information And Sales Area

Table 49: MyBioSource.com. Products Portfolio

Table 50: Novus Biologicals Basic Information And Sales Area

Table 51: Novus Biologicals. Products Portfolio

Table 52: viva Systems Biology Basic Information And Sales Area

Table 53: viva Systems Biology. Products Portfolio

Table 54: lifeSnan RioSciences Basic Information And Sales Area

Table 55: lifeSnan RioSciences. Products Portfolio

Table 56: Global Market Value (USD Million) (2025-2032) By Application

Table 57: Global Market Share (%) By Application (2032)

Table 58: Global Market Value (USD Million) (2025-2032) By Types

Table 59: Global Market Share (%) By Types (2032)

Table 60: Global Mycoplasma Detection Kit Market Value (USD Million) By Region

Table 61: Global Mycoplasma Detection Kit Market Share (%) By Region (2025-2032)

Table 62: North America Market Value (USD Million) (2025-2032) By Country

Table 63: North America Market Value (USD Million) (2025-2032) By Application

Table 64: North America Market Value (USD Million) (2025-2032) By Types

Table 65: Europe Market Value (USD Million) (2025-2032) By Country

Table 66: Europe Market Value (USD Million) (2025-2032) By Application

Table 67: Europe Market Value (USD Million) (2025-2032) By Types

Table 68: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 69: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 70: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 71: South America Market Value (USD Million) (2025-2032) By Country

Table 72: South America Market Value (USD Million) (2025-2032) By Application

Table 73: South America Market Value (USD Million) (2025-2032) By Types

Table 74: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 75: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 76: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 77: Research Programs/Design For This Report

Table 78: Key Data Information From Secondary Sources

Table 79: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Mycoplasma Detection Kit Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	250.00 million
Revenue forecast in 2033	632.38 million
Growth rate	CAGR of 12.3% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	GeneCopoeia, Inc.; InvivoGen; Captivate Bio; Creative Diagnostics; SouthernBiotech; Lonza; GenWay Biotech, Inc.; Abcam; R&D Systems; MyBioSource.com; Novus Biologicals; viva Systems Biology; lifeSnan RioSciences
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Restraints2 items

Opportunities2 items

Challenges2 items

Market Segmentation

Loading chart…

Mycoplasma Detection Kit Segmentation Breakdown7 items

Application

Hospital

Clinics

Testing Institutions

Types

Colloidal Gold Type

Enzyme Linked Immunosorbent

Regional Insights

Loading chart…

Competitive Landscape

GeneCopoeia, Inc.: Regional expansion in Asia-Pacific with diagnostics tailored to poultry research

InvivoGen: Innovation pipeline focused on CRISPR-based detection methods for high-sensitivity applications

Captivate Bio: OEM tie-ups to integrate kits with automated laboratory workflows

Creative Diagnostics: Cost advantages via localized production in China for price-sensitive markets

Lonza: Vertical integration of reagent supply chains to mitigate raw material volatility

R&D Systems: Expansion of multiplexed immunoassay portfolios for high-throughput clinical labs

Key Mycoplasma Detection Kit Companies13 items

GeneCopoeia, Inc.

InvivoGen

Captivate Bio

Creative Diagnostics

SouthernBiotech

Lonza

GenWay Biotech, Inc.

Abcam

R&D Systems

MyBioSource.com

Novus Biologicals

viva Systems Biology

lifeSnan RioSciences

Market Ecosystem

Raw material/component suppliers — supply reagents, buffers, and plastics for kit manufacturing

Technology providers — design molecular detection methods (e.g., PCR, ELISA) and software algorithms

OEMs/Manufacturers — produce and validate detection kits under quality assurance protocols

System integrators — incorporate kits into automated diagnostic platforms and lab systems

Distributors/Channel partners — facilitate B2B sales and supply chain logistics for healthcare providers

Service providers/After-sales — deliver training, maintenance, and technical troubleshooting

Regulators/Standards bodies — enforce CE, FDA, or ISO compliance for diagnostic accuracy and safety

Recent Industry Insights

Analyst Overview

Table of Contents